Movement Alert｜Teva Pharmaceutical Rises 5.15% in Pre-Market Trading, Q2 Revenue Beats Expectations Despite Significant EPS Miss

Market Focus

07/29

On July 29, Teva Pharmaceutical rose 5.15% in pre-market trading, trading at $33.3/share, with turnover of $856,100.

The movement was primarily driven by the company's Q2 earnings release. Teva reported quarterly revenue of $4.142 billion, exceeding the analyst consensus estimate of $4.047 billion. However, adjusted earnings per share came in at just $0.02, missing the consensus estimate of $0.25 by 92% and representing a nearly 97% decline from $0.66 per share in the year-ago period. Despite the significant EPS shortfall, the top-line beat appears to be supporting pre-market price action.

The company had previously delivered a strong Q1, with adjusted EPS of $0.53 beating the $0.48 estimate by over 10% on revenue of $3.982 billion. Full-year Non-GAAP EPS guidance remains at $1.91 to $2.11. Recent pipeline developments include exclusive rights to commercialize Polpharma's biosimilar candidate to Ocrevus, an NDA submission for ecopipam in pediatric Tourette syndrome, and the European launch of Eylea biosimilar Ahzantive.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1121031859"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121031859\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121031859?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-29 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121031859","market":"us","top_or_hot":-1,"title":"Movement Alert｜Teva Pharmaceutical Rises 5.15% in Pre-Market Trading, Q2 Revenue Beats Expectations Despite Significant EPS Miss","media":"Market Focus","content":"<p><p>On July 29, Teva Pharmaceutical rose 5.15% in pre-market trading, trading at $33.3/share, with turnover of $856,100.</p><p>The movement was primarily driven by the company's Q2 earnings release. Teva reported quarterly revenue of $4.142 billion, exceeding the analyst consensus estimate of $4.047 billion. However, adjusted earnings per share came in at just $0.02, missing the consensus estimate of $0.25 by 92% and representing a nearly 97% decline from $0.66 per share in the year-ago period. Despite the significant EPS shortfall, the top-line beat appears to be supporting pre-market price action.</p><p>The company had previously delivered a strong Q1, with adjusted EPS of $0.53 beating the $0.48 estimate by over 10% on revenue of $3.982 billion. Full-year Non-GAAP EPS guidance remains at $1.91 to $2.11. Recent pipeline developments include exclusive rights to commercialize Polpharma's biosimilar candidate to Ocrevus, an NDA submission for ecopipam in pediatric Tourette syndrome, and the European launch of Eylea biosimilar Ahzantive.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Teva Pharmaceutical Rises 5.15% in Pre-Market Trading, Q2 Revenue Beats Expectations Despite Significant EPS Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Teva Pharmaceutical Rises 5.15% in Pre-Market Trading, Q2 Revenue Beats Expectations Despite Significant EPS Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-29 19:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 29, Teva Pharmaceutical rose 5.15% in pre-market trading, trading at $33.3/share, with turnover of $856,100.</p><p>The movement was primarily driven by the company's Q2 earnings release. Teva reported quarterly revenue of $4.142 billion, exceeding the analyst consensus estimate of $4.047 billion. However, adjusted earnings per share came in at just $0.02, missing the consensus estimate of $0.25 by 92% and representing a nearly 97% decline from $0.66 per share in the year-ago period. Despite the significant EPS shortfall, the top-line beat appears to be supporting pre-market price action.</p><p>The company had previously delivered a strong Q1, with adjusted EPS of $0.53 beating the $0.48 estimate by over 10% on revenue of $3.982 billion. Full-year Non-GAAP EPS guidance remains at $1.91 to $2.11. Recent pipeline developments include exclusive rights to commercialize Polpharma's biosimilar candidate to Ocrevus, an NDA submission for ecopipam in pediatric Tourette syndrome, and the European launch of Eylea biosimilar Ahzantive.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦制药","start_time":0,"source_url":"","article_id":"1121031859","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121031859","pubTimestamp":1785323408,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 29, Teva Pharmaceutical rose 5.15% in pre-market trading, trading at $33.3/share, with turnover of $856,100.The movement was primarily driven by the company's Q2 earnings release. Teva...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"走势提醒|梯瓦制药盘前交易上涨 5.15%，尽管每股收益大幅下滑，第二季度收入仍超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"On July 29, Teva Pharmaceutical rose 5.15% in pre-market trading, trading at $33.3/share, with turnover of $856,100.The movement was primarily driven by the company's Q2 earnings release. Teva reported quarterly revenue of $4.142 billion, exceeding the analyst consensus estimate of $4.047 billion. However, adjusted earnings per share came in at just $0.02, missing the consensus estimate of $0.25 by 92% and representing a nearly 97% decline from $0.66 per share in the year-ago period. Despite the significant EPS shortfall, the top-line beat appears to be supporting pre-market price action.The company had previously delivered a strong Q1, with adjusted EPS of $0.53 beating the $0.48 estimate by over 10% on revenue of $3.982 billion. Full-year Non-GAAP EPS guidance remains at $1.91 to $2.11. Recent pipeline developments include exclusive rights to commercialize Polpharma's biosimilar candidate to Ocrevus, an NDA submission for ecopipam in pediatric Tourette syndrome, and the European launch of Eylea biosimilar Ahzantive.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}